Conference Call and Webcast Scheduled for 8:30 AM ET
RA’ANANA, Israel & NEW YORK--(BUSINESS WIRE)--Nov. 5, 2018--
UroGen Pharma Ltd. (NASDAQ:URGN) today announced that it will report
third quarter 2018 financial results on Monday, November 12, 2018, prior
to the open of the market. The announcement will be followed by a live
audio webcast and conference call at 8:30AM Eastern Time.
Audio Webcast
The webcast will be made available on the Investors section of the
Company’s website at http://investors.urogen.com.
Following the live audio webcast, a replay will be available on the
Company's website for approximately two weeks.
Dial-In Information
Live (U.S. / Canada): 1 (888) 771-4371
Live (International): 1
(847) 585-4405
Confirmation number: 47697839
About UroGen Pharma Ltd.
UroGen Pharma Ltd. (Nasdaq:URGN) is a clinical-stage biopharmaceutical
company developing advanced non-surgical treatments to address unmet
needs in the field of urology, with a focus on uro-oncology. UroGen has
developed RTGel™, a proprietary sustained release, hydrogel-based
platform technology that has the potential to improve therapeutic
profiles of existing drugs. UroGen’s sustained release technology is
designed to enable longer exposure of the urinary tract tissue to
medications, making local therapy a potentially more effective treatment
option. UroGen’s lead product candidates, UGN-101 and UGN-102, are
designed to potentially remove tumors by non-surgical means and to treat
several forms of non-muscle invasive urothelial cancer, including
low-grade upper tract urothelial carcinoma and bladder cancer,
respectively. UroGen is headquartered New York, NY with offices in
Ra’anana, Israel and Los Angeles, CA.
View source version on businesswire.com: https://www.businesswire.com/news/home/20181105005271/en/
Source: UroGen Pharma Ltd.
UROGEN:
Kate Bechtold, 914-552-0456
Director, Corporate
Communications & Investor Relations
Kate.Bechtold@UroGen.com
